Comparative analysis of business models of top pharmaceutical manufacturing companies: financial analysis
DOI:
https://doi.org/10.21518/1561-5936-2020-10-43-52Keywords:
pharmaceutical manufacturers, business model, financial analysis, performance evaluation, profitability, equity and debt capital, debt burden, receivables and payablesAbstract
Introduction. Earlier, the comparative analysis of the commercial and investment activities of the companies that play the key roles in the investment processes in the Russian pharmaceutical industry and operate within the four main business models (biotechnological, generic, specialized pharmaceutical companies, active pharmaceutical ingredient (API) manufacturers) has been conducted. No full assessment of the companies’ activities is conceivable without a financial analysis of their activities to identify the risks of investment activities.Objective of the study. A detailed comparative analysis of the financial standing of domestic pharmaceutical manufacturers operating within the selected business models for further identification of potential financial risks for investors. Research procedure and article structure. Analysis of RAS statements (forms 1 and 2) of 72 over 500 million revenue companies grouped together as selectedbusiness models for the period from 2015 to 2019.Results. The researchers provided a detailed description of the commercial activities of domestic pharmaceutical companies within the business models under consideration. The companies within various business models showed positive revenue growth rates over the past five years. All business models demonstrate consistently high business profitability and a significant share of own capital in the asset profile.Conclusion. The results of the study show the stable financial standing of the pharmaceutical companies within various business models. The biotechnology sector companies that are the most attractive for investments have the highest quality financial standing. The specialized and generic companies show similar consistently strong performance. API manufacturers that the companies with relatively small revenues are actively developing and are attractive to restrained budget investors.References
Трофимова Е.О., Ясинская Л.Е. Количественный анализ продуктовых портфелей российских фармацевтических производителей и их классификация. Ремедиум. 2019;(11):8-15. doi: 10.21518/1561-5936-2019-11-8-15.
Ясинская Л.Е., Трофимова Е.О. Сравнительная характеристика бизнес-моделей лидеров фармацевтического производства: аспекты коммерческой деятельности. Ремедиум. 2020;(1-3):50-59. doi: 10.21518/1561-5936-2020-1-2-3-50-59.
Ясинская Л.Е. Сравнительная характеристика бизнес- моделей лидеров фармацевтического производства: аспекты инвестиционной деятельности. Ремедиум. 2020;(4-6):71-78. doi: 10.21518/1561-5936-2020-4-5-6-66-78.
Ясинская Л.Е., Трофимова Е.О. Государственная финансовая поддержка фармацевтической и медицинской промышленности. Ремедиум. 2016;(10):6-16. doi: 10.21518/1561- 5936-2016-10-6-15.
Ясинская Л.Е. Финансовый анализ отечественных производственных фармацевтических предприятий. Ремедиум. 2017;(4):16-24. doi: 10.21518/1561-5936-2017-4-16-24.
Downloads
Published
Issue
Section
License
Authors retain copyright and grant the journal right of the first publication. The article simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
By submitting the article and accompanying files (hereinafter – the “Work”) the author (all the authors of the work, if it is created in co-authorship) agrees that he provides OAO Izdatelstvo Meditsina exclusive and perpetual right to use the work free of charge (exclusive, perpetual and royalty-free license) on the territory of Russia and foreign countries in the following ranges and volume:
- the publication of works on paper and / or electronic format, producing reprints of works, placing it on the Internet, both in the open and paid access, sending works metadata or full text indexing to various databases and repositories;
- reproduction of the work, i.e. the production of one or more copies of a work or part thereof in any material form, including in the form of audio or video recording. Recording on electronic media, including recording in computer memory, is also considered as a reproduction;
- distribution of works through sale or other alienation of its original or copies;
- public display of the work, that is, any demonstration of the original or copy of a work, either directly or on the screen using film, slide, television pictures or other technical means, as well as a demonstration of individual frames of an audiovisual work without concern for their order, either directly or with the help of technical means in a place open for free visits, or in a place where a significant number of individuals do not belong to the normal family, regardless of the perceived in the place of its display or elsewhere at the same time demonstrating product;
- import-export of the work or its parts for any lawful purpose (paid and gratis);
- translation or other processing of the works;
- bringing the work to the public so that anyone can access the work from any place and at any time of their choice;
- accommodation of works or parts thereof in a variety of collections of similar works;
- granting of rights in full or in part to third (physical and legal) persons at both the paid and free of charge.
Author’s items are not provided. The title is available by subscription.
